Enrique Gallardo Díaz

Institute of Research and Innovation Parc Tauli — Spain

Medicine · Health Sciences

10h-index362citations73works22.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(17), Radiopharmaceutical Chemistry and Applications(12), Renal cell carcinoma treatment(10), Cancer Immunotherapy and Biomarkers(8), Economic and Financial Impacts of Cancer(6)

Publications72 total

PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.
Journal of Clinical Oncology·2025· 1 cited
External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)
Clinical & Translational Oncology·2025· 1 citedOpen Access
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
Journal of Clinical Oncology·2024· 7 cited
Catheter – Related Thrombosis in Cancer Patients: Data from the Registry of Thrombosis and Neoplasia of Seom (Teseo)
SSRN Electronic Journal·2024Open Access
1783P PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Annals of Oncology·2023· 1 citedOpen Access
2149P Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Annals of Oncology·2023· 1 citedOpen Access
1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Annals of Oncology·2023Open Access
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Clinical & Translational Oncology·2023· 9 citedOpen Access
Efficient and low-cost temperature automated system for aquariums in fry hatcheries using control algorithms
2023Open Access
Design of control mechanisms for electrical groups based on IOT technology for monitoring operating parameters
AIP conference proceedings·2023· 1 citedOpen Access
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)
Annals of Oncology·2022
1659TiP A Spanish observational study for MOLecular characterization of THYroid carcinoma: MOLTHY Project – TTCC-2020-02
Annals of Oncology·2022
Low Cost System Based on Infrared Technology for Water Management
Journal of Physics Conference Series·2022· 1 citedOpen Access
589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
Annals of Oncology·2021· 1 cited
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.
Journal of Clinical Oncology·2021· 35 cited
Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism in Spain.
Journal of Clinical Oncology·2021
Evaluation of comprehensive geriatric assessment impact in oncological decision-making process.
Journal of Clinical Oncology·2021
Design of an Affordable Module for Body Temperature Measurement and Capacity Control in Commercial Establishments to Avoid the Increase of Contages by Sars-Cov2
Review of International Geographical Education Online·2021
ECO Experts’ consensus on establishing renal cancer healthcare quality measures in Spain.
Journal of Clinical Oncology·2020
Cabazitaxel versus enzalutamide/abiraterone in CARD eligible mCRPC patients with or without germline HRR defects.
Journal of Clinical Oncology·2020· 1 cited
page 1 of 4Next →

Frequent Co-authors

Javier Puente(16), Aranzazu González del Alba(12), Núria Laínez(9), Jóse Ángel Arranz Arija(7), Alejo Rodríguez‐Vida(6), Begoña P. Valderrama(6), Miguel Ángel Climent(6), Sergio Vázquez‐Estévez(6), Ignacio Durán(6), Montserrat Domènech(5), Begoña Mellado(5), M.I. Sáez(5), Raquel Luque(5), Miguel Á. Climent Durán(5), Xavier García del Muro(5), Begoña Pérez‐Valderrama(5), M.J. Méndez Vidal(5), José Carlos Villa Guzmán(5), Daniel Castellano(5), María José Méndez-Vidal(5)